Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 750, 135769
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's DiseaseMolecular Therapy, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's ModelsScience, 2006
- Harnessing HIV for therapy, basic research and biotechnologyTrends in Biotechnology, 2005
- Repopulation of Rat Liver by Fetal Hepatoblasts and Adult Hepatocytes Transduced Ex Vivo With Lentiviral VectorsHepatology, 2003
- Prostate-specific targeting using PSA promoter-based lentiviral vectorsCancer Gene Therapy, 2001
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic NeuronsScience, 1993
- MPTP mechanisms of neurotoxicity and their implications for Parkinson's diseaseEuropean Journal of Pharmacology: Molecular Pharmacology, 1991